Interleukin-6 and oncostatin M are elevated in liver disease in conjunction with candidate hepatocellular carcinoma biomarker GP73

Hongyan Liang, Timothy M. Block, Mengjun Wang, Bradley Nefsky, Ronald Long, Julie Hafner, Anand S. Mehta, Jorge Marrero, Robert Gish, Pamela A. Norton

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

The Golgi phosphoprotein GP73 is elevated in the circulation of individuals with a diagnosis of hepatocellular carcinoma. Its usefulness as a biomarker of HCC is questioned, since it has also been reported to be elevated in the circulation of people with liver cirrhosis. Regulation of GP73 by inflammatory cytokines is therefore of interest. The interleukin-6 (IL-6) family cytokines were tested for effects on GP73 mRNA and/or protein levels in human hepatoblastoma HepG2 cells. Levels of GP73 mRNA and protein were up-regulated in HepG2 cells following treatment with either proinflammatory cytokine IL-6 or the related cytokine oncostatin M (OSM). Induction required the shared receptor subunit gp130, and correlated with increased tyrosine phosphorylation of STAT3. Maximal cytokine-mediated induction was not observed in the presence of protein synthesis inhibitor cycloheximide, suggesting additional regulatory factors play an important role. ELISA measurement of GP73 and IL-6 levels in the sera of patients with pre-malignant liver disease revealed a significant correlation between circulating levels of the two proteins. Similarly, a sensitive ELISA assay was developed to measure circulating OSM. OSM levels were elevated 6-7 fold in sera from patients with either cirrhosis or HCC relative to controls without liver disease. Although there was an association between levels of GP73 and OSM in serum from people with liver cirrhosis, there was not a statistically significant correlation in HCC, suggesting that the role of the cytokines in determining circulating levels may be complex. To our knowledge, this is the first report of OSM elevation being associated with liver disease.

Original languageEnglish (US)
Pages (from-to)161-171
Number of pages11
JournalCancer Biomarkers
Volume11
Issue number4
DOIs
StatePublished - 2012

Fingerprint

Oncostatin M
Liver Diseases
Hepatocellular Carcinoma
Interleukin-6
Biomarkers
Cytokines
Hep G2 Cells
Liver Cirrhosis
Serum
Enzyme-Linked Immunosorbent Assay
Hepatoblastoma
Messenger RNA
Proteins
Protein Synthesis Inhibitors
Phosphoproteins
Cycloheximide
Tyrosine
Fibrosis
Phosphorylation

Keywords

  • cirrhosis
  • Golgi phosphoprotein
  • GOLM1
  • GOLPH2

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Genetics

Cite this

Interleukin-6 and oncostatin M are elevated in liver disease in conjunction with candidate hepatocellular carcinoma biomarker GP73. / Liang, Hongyan; Block, Timothy M.; Wang, Mengjun; Nefsky, Bradley; Long, Ronald; Hafner, Julie; Mehta, Anand S.; Marrero, Jorge; Gish, Robert; Norton, Pamela A.

In: Cancer Biomarkers, Vol. 11, No. 4, 2012, p. 161-171.

Research output: Contribution to journalArticle

Liang, H, Block, TM, Wang, M, Nefsky, B, Long, R, Hafner, J, Mehta, AS, Marrero, J, Gish, R & Norton, PA 2012, 'Interleukin-6 and oncostatin M are elevated in liver disease in conjunction with candidate hepatocellular carcinoma biomarker GP73', Cancer Biomarkers, vol. 11, no. 4, pp. 161-171. https://doi.org/10.3233/CBM-2012-00276
Liang, Hongyan ; Block, Timothy M. ; Wang, Mengjun ; Nefsky, Bradley ; Long, Ronald ; Hafner, Julie ; Mehta, Anand S. ; Marrero, Jorge ; Gish, Robert ; Norton, Pamela A. / Interleukin-6 and oncostatin M are elevated in liver disease in conjunction with candidate hepatocellular carcinoma biomarker GP73. In: Cancer Biomarkers. 2012 ; Vol. 11, No. 4. pp. 161-171.
@article{8ac2b0c089bb4812833f3335af57999a,
title = "Interleukin-6 and oncostatin M are elevated in liver disease in conjunction with candidate hepatocellular carcinoma biomarker GP73",
abstract = "The Golgi phosphoprotein GP73 is elevated in the circulation of individuals with a diagnosis of hepatocellular carcinoma. Its usefulness as a biomarker of HCC is questioned, since it has also been reported to be elevated in the circulation of people with liver cirrhosis. Regulation of GP73 by inflammatory cytokines is therefore of interest. The interleukin-6 (IL-6) family cytokines were tested for effects on GP73 mRNA and/or protein levels in human hepatoblastoma HepG2 cells. Levels of GP73 mRNA and protein were up-regulated in HepG2 cells following treatment with either proinflammatory cytokine IL-6 or the related cytokine oncostatin M (OSM). Induction required the shared receptor subunit gp130, and correlated with increased tyrosine phosphorylation of STAT3. Maximal cytokine-mediated induction was not observed in the presence of protein synthesis inhibitor cycloheximide, suggesting additional regulatory factors play an important role. ELISA measurement of GP73 and IL-6 levels in the sera of patients with pre-malignant liver disease revealed a significant correlation between circulating levels of the two proteins. Similarly, a sensitive ELISA assay was developed to measure circulating OSM. OSM levels were elevated 6-7 fold in sera from patients with either cirrhosis or HCC relative to controls without liver disease. Although there was an association between levels of GP73 and OSM in serum from people with liver cirrhosis, there was not a statistically significant correlation in HCC, suggesting that the role of the cytokines in determining circulating levels may be complex. To our knowledge, this is the first report of OSM elevation being associated with liver disease.",
keywords = "cirrhosis, Golgi phosphoprotein, GOLM1, GOLPH2",
author = "Hongyan Liang and Block, {Timothy M.} and Mengjun Wang and Bradley Nefsky and Ronald Long and Julie Hafner and Mehta, {Anand S.} and Jorge Marrero and Robert Gish and Norton, {Pamela A.}",
year = "2012",
doi = "10.3233/CBM-2012-00276",
language = "English (US)",
volume = "11",
pages = "161--171",
journal = "Cancer Biomarkers",
issn = "1574-0153",
publisher = "IOS Press",
number = "4",

}

TY - JOUR

T1 - Interleukin-6 and oncostatin M are elevated in liver disease in conjunction with candidate hepatocellular carcinoma biomarker GP73

AU - Liang, Hongyan

AU - Block, Timothy M.

AU - Wang, Mengjun

AU - Nefsky, Bradley

AU - Long, Ronald

AU - Hafner, Julie

AU - Mehta, Anand S.

AU - Marrero, Jorge

AU - Gish, Robert

AU - Norton, Pamela A.

PY - 2012

Y1 - 2012

N2 - The Golgi phosphoprotein GP73 is elevated in the circulation of individuals with a diagnosis of hepatocellular carcinoma. Its usefulness as a biomarker of HCC is questioned, since it has also been reported to be elevated in the circulation of people with liver cirrhosis. Regulation of GP73 by inflammatory cytokines is therefore of interest. The interleukin-6 (IL-6) family cytokines were tested for effects on GP73 mRNA and/or protein levels in human hepatoblastoma HepG2 cells. Levels of GP73 mRNA and protein were up-regulated in HepG2 cells following treatment with either proinflammatory cytokine IL-6 or the related cytokine oncostatin M (OSM). Induction required the shared receptor subunit gp130, and correlated with increased tyrosine phosphorylation of STAT3. Maximal cytokine-mediated induction was not observed in the presence of protein synthesis inhibitor cycloheximide, suggesting additional regulatory factors play an important role. ELISA measurement of GP73 and IL-6 levels in the sera of patients with pre-malignant liver disease revealed a significant correlation between circulating levels of the two proteins. Similarly, a sensitive ELISA assay was developed to measure circulating OSM. OSM levels were elevated 6-7 fold in sera from patients with either cirrhosis or HCC relative to controls without liver disease. Although there was an association between levels of GP73 and OSM in serum from people with liver cirrhosis, there was not a statistically significant correlation in HCC, suggesting that the role of the cytokines in determining circulating levels may be complex. To our knowledge, this is the first report of OSM elevation being associated with liver disease.

AB - The Golgi phosphoprotein GP73 is elevated in the circulation of individuals with a diagnosis of hepatocellular carcinoma. Its usefulness as a biomarker of HCC is questioned, since it has also been reported to be elevated in the circulation of people with liver cirrhosis. Regulation of GP73 by inflammatory cytokines is therefore of interest. The interleukin-6 (IL-6) family cytokines were tested for effects on GP73 mRNA and/or protein levels in human hepatoblastoma HepG2 cells. Levels of GP73 mRNA and protein were up-regulated in HepG2 cells following treatment with either proinflammatory cytokine IL-6 or the related cytokine oncostatin M (OSM). Induction required the shared receptor subunit gp130, and correlated with increased tyrosine phosphorylation of STAT3. Maximal cytokine-mediated induction was not observed in the presence of protein synthesis inhibitor cycloheximide, suggesting additional regulatory factors play an important role. ELISA measurement of GP73 and IL-6 levels in the sera of patients with pre-malignant liver disease revealed a significant correlation between circulating levels of the two proteins. Similarly, a sensitive ELISA assay was developed to measure circulating OSM. OSM levels were elevated 6-7 fold in sera from patients with either cirrhosis or HCC relative to controls without liver disease. Although there was an association between levels of GP73 and OSM in serum from people with liver cirrhosis, there was not a statistically significant correlation in HCC, suggesting that the role of the cytokines in determining circulating levels may be complex. To our knowledge, this is the first report of OSM elevation being associated with liver disease.

KW - cirrhosis

KW - Golgi phosphoprotein

KW - GOLM1

KW - GOLPH2

UR - http://www.scopus.com/inward/record.url?scp=84871595764&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871595764&partnerID=8YFLogxK

U2 - 10.3233/CBM-2012-00276

DO - 10.3233/CBM-2012-00276

M3 - Article

C2 - 23144154

AN - SCOPUS:84871595764

VL - 11

SP - 161

EP - 171

JO - Cancer Biomarkers

JF - Cancer Biomarkers

SN - 1574-0153

IS - 4

ER -